Physician profile
John Abraham
NPI 1962634535
$4,370.88
in general payments reported to CMS, 2019-2025
41 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,288 · 2020: $1,011 · 2021: $623 · 2022: $566 · 2023: $630 · 2024: $20.89 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $733.80 | 2021-2025 | Vraylar, Mavyret |
| Kowa Pharmaceuticals America, INC. | $551.91 | 2019-2021 | |
| Glaxosmithkline, LLC. | $350.92 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $273.34 | 2019-2025 | Farxiga |
| Novo Nordisk INC | $232.85 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $214.96 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $211.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.44 | 2019-2023 | Jardiance |
| Lilly USA, LLC | $157.33 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Allergan, INC. | $146.44 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.83 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $115.24 | 2023 | Monoferric |
| Pfizer INC. | $92.79 | 2019-2023 | |
| Abbott Laboratories | $79.30 | 2019-2023 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $77.78 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.